Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00443326
Status:
COMPLETED
Last Update Posted:
2016-01-20
First Post:
2007-03-01
Brief Title:
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Ascending Dose Study to Evaluate the Safety Pharmacokinetics and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety pharmacokinetics and efficacy Dose levels include 150mg and 300mg and will be given to each subject for a total of 6 doses Each dose for each subject will be given once every 2 weeks Subjects will followed for up to 300 days post the first dose of AMG 714
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None